(Reuters) – Patients on Eli Lilly’s weight-loss drug trial substantially regained weight after stopping treatment, according to a study published in journal JAMA on Monday.
Shares of Eli Lilly fell 2% in morning trading.
Eli Lilly’s drug tirzepatide is sold under brand name Zepbound for weight loss and has been available as Mounjaro for type 2 diabetes.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
